Cuidados Intensivos, Intermedios y Urgencias Pediátricas

2024

1. 4CMenB journey to the 10-year anniversary and beyond

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

2. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants

   Journal of Infectious Diseases, Vol. 229, pp. S112-S119

3. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

4. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

   Journal of Infectious Diseases, Vol. 229, pp. S100-S111

5. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

6. COVID-19 InfoVaccines: A WHO-supported educational project to promote COVID-19 vaccination information among professionals and the general population

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

7. Clinical-Hematological Changes and Predictors of Severity in Acute Food Protein–Induced Enterocolitis Syndrome Reactions at Oral Food Challenge: A Multicenter Observational Study

   Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 9, pp. 2454-2467.e8

8. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

9. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study

   The Lancet Infectious Diseases, Vol. 24, Núm. 8, pp. 817-828

10. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 78, Núm. 6, pp. 1732-1744

11. Erratum to «Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper» (Archivos de Bronconeumología (2024) 60(3) (161–170), (S0300289624000061), (10.1016/j.arbres.2024.01.004))

    Archivos de Bronconeumologia

12. External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care

    The Journal of infectious diseases, Vol. 229, Núm. 1, pp. S18-S24

13. External validation of a multivariable prediction model for identification of pneumonia and other serious bacterial infections in febrile immunocompromised children

    Archives of Disease in Childhood, Vol. 109, Núm. 1, pp. 58-66

14. GUANIN: an all-in-one GUi-driven analyzer for NanoString interactive normalization

    Bioinformatics, Vol. 40, Núm. 8

15. Genome-wide Association Study of Susceptibility to Respiratory Syncytial Virus Hospitalization in Young Children <5 Years of age

    Journal of Infectious Diseases, Vol. 230, Núm. 2, pp. e333-e341

16. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

    The Journal of experimental medicine, Vol. 221, Núm. 2

17. Host gene expression signatures to identify infection type and organ dysfunction in children evaluated for sepsis: a multicentre cohort study

    The Lancet Child and Adolescent Health, Vol. 8, Núm. 5, pp. 325-338

18. How Does the Burden of Respiratory Syncytial Virus Compare to Influenza in Spanish Adults?

    Influenza and other Respiratory Viruses, Vol. 18, Núm. 6

19. Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023

    Nature Medicine, Vol. 30, Núm. 6, pp. 1559-1563

20. Integration and validation of host transcript signatures, including a novel 3-transcript tuberculosis signature, to enable one-step multiclass diagnosis of childhood febrile disease

    Journal of Translational Medicine, Vol. 22, Núm. 1